G1 Therapeutics developed a lung cancer drug called Cosela, which was FDA-approved in 2021. The company was recently acquired by Pharmacosmos for $405 million. Cosela is an intravenously infused therapy that protects bone marrow from chemotherapy’s effects by blocking CDK4/6 proteins. G1 reported $46.3 million in product sales in 2023, but faced challenges in expanding the drug’s use beyond lung cancer. The acquisition by Pharmacosmos will help make Cosela more widely available globally. G1 Therapeutics was founded in 2008 and spun out of the University of North Carolina at Chapel Hill. The acquisition is expected to close in the third quarter of this year.
Source link
Path Forward for Cancer Biotech G1 Therapeutics Is $405M Acquisition by Pharmacosmos
